Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2019 Nov;8(15):6566-6577.
doi: 10.1002/cam4.2502. Epub 2019 Sep 11.

Changes in conditional net survival and dynamic prognostic factors in patients with newly diagnosed metastatic prostate cancer initially treated with androgen deprivation therapy

Shintaro Narita  1   2 , Kyoko Nomura  3 , Shingo Hatakeyama  4   2 , Masahiro Takahashi  5   2 , Toshihiko Sakurai  6   2 , Sadafumi Kawamura  7   2 , Senji Hoshi  8   2 , Masanori Ishida  9   2 , Toshiaki Kawaguchi  10   2 , Shigeto Ishidoya  11   2 , Jiro Shimoda  9   2 , Hiromi Sato  1 , Koji Mitsuzuka  5   2 , Tatsuo Tochigi  7   2 , Norihiko Tsuchiya  6   2 , Chikara Ohyama  4   2 , Yoichi Arai  5   2 , Kengo Nagashima  12 , Tomonori Habuchi  1   2
Affiliations
Multicenter Study

Changes in conditional net survival and dynamic prognostic factors in patients with newly diagnosed metastatic prostate cancer initially treated with androgen deprivation therapy

Shintaro Narita et al. Cancer Med. 2019 Nov.

Abstract

Background: The purpose of this study was to identify predictive factors associated with conditional net survival in patients with metastatic hormone-naive prostate cancer (mHNPC) initially treated with androgen deprivation therapy (ADT).

Methods: At nine hospitals in Tohoku, Japan, the medical records of 605 consecutive patients with mHNPC who initially received ADT were retrospectively reviewed. The Pohar Perme estimator was used to calculate conditional net cancer-specific survival (CSS) and overall survival (OS) for up to 5 years subsequent to the diagnosis. Using multiple imputation, proportional hazard ratios for conditional CSS and OS were calculated with adjusted Cox regression models.

Results: During a median follow up of 2.95 years, 208 patients died, of which 169 died due to progressive prostate cancer. At baseline, the 5-year CSS and OS rates were 65.5% and 58.2%, respectively. Conditional 5-year net CSS and OS survival gradually increased for all the patients. In patients given a 5-year survivorship, the conditional 5-year net CSS and OS rates improved to 0.906 and 0.811, respectively. Only the extent of disease score (EOD) ≥2 remained a prognostic factor for CSS and OS up to 5 years; as survival time increased, other variables were no longer independent prognostic factors.

Conclusions: The conditional 5-year net CSS and OS in patients with mHNPC gradually increased; thus, the risk of mortality decreased with increasing survival. The patient's risk profile changed over time. EOD remained an independent prognostic factor for CSS and OS after 5-year follow-up. Conditional net survival can play a role in clinical decision-making, providing intriguing information for cancer survivors.

Keywords: androgen deprivation therapy; conditional survival; metastatic hormone-naive; net survival; prostate cancer.

PubMed Disclaimer

Conflict of interest statement

Tomonori Habuchi has acted as a paid consultant for Janssen and Sanofi for work performed outside the current study.

Figures

Figure 1
Figure 1
Flowchart of study enrollment
Figure 2
Figure 2
Conditional overall survival curve for patients with metastatic hormone‐naive prostate cancer initially treated with androgen deprivation therapy
Figure 3
Figure 3
Conditional 5‐y net overall survival (OS) rates relative to the baseline rate. The bars indicate the conditional 5‐y net OS rates for patients with metastatic hormone‐naive prostate cancer initially treated with androgen deprivation therapy
Figure 4
Figure 4
Conditional overall survival curves stratified by the bone metastasis extent of disease (EOD) score. (A): EOD ≤1. (B): EOD ≥2
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9‐29. - PubMed
    1. Mosillo C, Iacovelli R, Ciccarese C, et al. De novo metastatic castration sensitive prostate cancer: State of art and future perspectives. Cancer Treat Rev. 2018;70:67‐74. - PubMed
    1. Buzzoni C, Auvinen A, Roobol MJ, et al. Metastatic prostate cancer incidence and prostate‐specific antigen testing: new insights from the european randomized study of screening for prostate cancer. Eur Urol. 2015;68(5):885‐890. - PMC - PubMed
    1. Weiner AB, Matulewicz RS, Eggener SE, Schaeffer EM. Increasing incidence of metastatic prostate cancer in the United States (2004–2013). Prostate Cancer Prostatic Dis. 2016;19(4):395‐397. - PubMed
    1. Vale CL, Burdett S, Rydzewska L, et al. Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone‐sensitive prostate cancer: a systematic review and meta‐analyses of aggregate data. Lancet Oncol. 2016;17(2):243‐256. - PMC - PubMed

Publication types

Substances